ASCO 2021 | Larotrectinib, a TRK inhibitor for patients with solid tumors
Sébastien Perreault
• 25 May 2021
Sébastien Perreault, MD, FRCPC, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Canada, discusses larotrectinib, a selective TRK inhibitor currently approved by the US FDA for the treatment of pediatric and adult patients with advanced TRK fusion-positive solid tumors. Dr Perreault outlines the results of this agent in pediatric and adult patients with solid tumors, including central nervous system cancers. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Sébastien Perreault, MD, FRCPC has received an advisory board role and conference support from Bayer, conference support from Eisai, and research support from Novartis.
